celecoxib has been researched along with Carcinoma, Basal Cell in 8 studies
Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We then assessed the effects of celecoxib on the development of BCCs in a 3-year, double-blinded, randomized clinical trial in 60 (PTCH1(+/-)) patients with the basal cell nevus syndrome." | 5.14 | Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. ( Aszterbaum, M; Athar, M; Barsanti, F; Bickers, DR; Cappola, C; Epstein, EH; Estevez, N; Hebert, J; Hwang, J; Khaimskiy, Y; Kim, A; Kohn, MA; Kopelovich, L; Lu, Y; McCulloch, CE; So, PL; Tang, JY; Tang, X, 2010) |
| "CDH11 expressing basal-like breast carcinomas and other CDH11 expressing malignancies exhibit poor prognosis." | 1.40 | Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. ( Anastasiadis, PZ; Assefnia, S; Brenner, M; Brown, ML; Byers, SW; Dakshanamurthy, S; Foley, DW; Guidry Auvil, JM; Haigh, D; Hampel, C; Kallakury, B; Shapiro, L; Uren, A, 2014) |
| " Neither association was observed when stratified by NSAID type (aspirin and other NSAIDs), nor did dose-response patterns emerge by frequency of use (average days per month)." | 1.38 | Use of nonsteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States Radiologic Technologists study. ( Alexander, BH; Cahoon, EK; Doody, MM; Freedman, DM; Linet, MS; Rajaraman, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assefnia, S | 1 |
| Dakshanamurthy, S | 1 |
| Guidry Auvil, JM | 1 |
| Hampel, C | 1 |
| Anastasiadis, PZ | 1 |
| Kallakury, B | 1 |
| Uren, A | 1 |
| Foley, DW | 1 |
| Brown, ML | 1 |
| Shapiro, L | 1 |
| Brenner, M | 1 |
| Haigh, D | 1 |
| Byers, SW | 1 |
| Tang, JY | 1 |
| Aszterbaum, M | 1 |
| Athar, M | 1 |
| Barsanti, F | 1 |
| Cappola, C | 1 |
| Estevez, N | 1 |
| Hebert, J | 1 |
| Hwang, J | 1 |
| Khaimskiy, Y | 1 |
| Kim, A | 1 |
| Lu, Y | 1 |
| So, PL | 1 |
| Tang, X | 1 |
| Kohn, MA | 1 |
| McCulloch, CE | 1 |
| Kopelovich, L | 1 |
| Bickers, DR | 1 |
| Epstein, EH | 1 |
| Meyskens, FL | 1 |
| McLaren, CE | 1 |
| Elmets, CA | 1 |
| Viner, JL | 1 |
| Pentland, AP | 1 |
| Cantrell, W | 1 |
| Lin, HY | 1 |
| Bailey, H | 1 |
| Kang, S | 1 |
| Linden, KG | 1 |
| Heffernan, M | 1 |
| Duvic, M | 1 |
| Richmond, E | 1 |
| Elewski, BE | 1 |
| Umar, A | 1 |
| Bell, W | 1 |
| Gordon, GB | 1 |
| Cahoon, EK | 1 |
| Rajaraman, P | 1 |
| Alexander, BH | 1 |
| Doody, MM | 1 |
| Linet, MS | 1 |
| Freedman, DM | 1 |
| Liebman, TN | 1 |
| Stein, JA | 1 |
| Polsky, D | 1 |
| Wilgus, TA | 1 |
| Koki, AT | 1 |
| Zweifel, BS | 1 |
| Kusewitt, DF | 1 |
| Rubal, PA | 1 |
| Oberyszyn, TM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Celecoxib In Subjects With Actinic Keratoses[NCT00027976] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2001-12-31 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for celecoxib and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; | 2010 |
Celecoxib may decrease some skin cancers.
Topics: Animals; Carcinoma, Basal Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Mice; Pyrazoles; Ski | 2010 |
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous | 2010 |
5 other studies available for celecoxib and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Arthritis, Rheumatoid; Blotting, Western; Breast Neoplas | 2014 |
Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?
Topics: Adenoma; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; | 2010 |
Use of nonsteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States Radiologic Technologists study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Basal Cell; Cele | 2012 |
Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: is there a role for these agents?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; | 2003 |